ASH 2010 Conference Coverage
Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.
Patients with kataegis, a recently discovered phenomenon in which multiple mutations cluster in a few hotspots in a genome, have less invasive tumors and better prognoses.
Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.
The risk of developing cancer increases in people who experience heart failure after their first heart attack compared with people who experience no heart failure after their first heart attack.
Despite confirmation of a link between routine Pap smear screening and a lower risk of developing cervical cancer in women older than 65 years, most US health guidelines discourage older women from undergoing routine Pap smears unless they have pre-existing risk factors.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries
Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.
Fasting during chemotherapy treatment may increase the presence of cancer-killing T cells, according to recent study data.
Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.
A Systematic Review and Meta-analysis of the Risk of Diarrhea Associated With Vandetanib Treatment in Carcinoma Patients
[OncoTargets and Therapy] This research examines overall risks of all-grade and high-grade diarrhea during vandetanib treatment, to gain a better understanding of its prediction and management.
- Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma
- How Can We Have a Cancer Cure Moonshot if We're Short of Fuel?
- High-Fat Mediterranean Diet Can Protect Against Cancer
- Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation Carriers
- HPV Vaccination Program Reduces Cervical Cell Anomalies in Young Women
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Blood Biomarker Is Predictive of Risk for Colon Cancer Recurrence
- Hypermutated Hotspots Are Biomarkers Predictive of Better Outcomes in Breast Cancer
- Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer
- Cancer Risk Higher in Patients With Heart Failure After a First Heart Attack
- Routine Pap Smears Improve Cervical Cancer Risk in Women Older Than 65 Years
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|